Many variables complicate second‑line treatment choice

Clinical factors may include:

Performance status1



Insufficient response to high-
dose chemotherapy2

Disease severity1

Nonclinical factors include personal considerations, such as:

Continuing treatment
with current care team3

Patient refusal1


Distance from
treatment center3


While clinical factors contribute to treatment decisions, there are other considerations for DLBCL patients, such as insurance and financial concerns, distance from treatment centers, and a desire to continue with their current care team.1,3,4

*Comorbidity evaluation may include examination of pulmonary, hepatic, cardiovascular, renal, and infectious parameters, as well as malignancy and pregnancy status.1

Biologic and physiologic age may be considered.1

Shared decision-making

Shared decision-making helps ensure the treatment choice is determined by evidence-based information as well as patient preferences and goals.1,5

Following an assessment of clinical factors, consider MONJUVI as a second-line treatment for adult patients with R/R DLBCL who are transplant ineligible and prefer to6:

Continue treatment with
current care team

Receive outpatient treatment

Access treatment in a local office
or clinic

Receive treatment in a timely manner

MONJUVI should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage IRRs.